1
项与 Neoantigen-Targeted Dendritic Cell Vaccine(Jonsson Comprehensive Cancer Center) 相关的临床试验A Pilot Study to Evaluate the Safety and Feasibility of Neoantigen-Targeted Dendritic Cell Vaccination in Diffuse Hemispheric Glioma, H3 G34-Mutant
This phase I trial tests the safety and side effects, and best dose of a vaccine (neoantigen-target ppDC) in treating patients with H3 G34-mutant diffuse hemispheric glioma. Vaccines made from the patient's own white blood cells and peptide-pulsed dendritic cells may help the body build an effective immune response to kill tumor cells. Giving neoantigen-targeted ppDC may be safe, tolerable and/or effective in treating patients with diffuse hemispheric glioma with a H3 G34 mutation.
100 项与 Neoantigen-Targeted Dendritic Cell Vaccine(Jonsson Comprehensive Cancer Center) 相关的临床结果
100 项与 Neoantigen-Targeted Dendritic Cell Vaccine(Jonsson Comprehensive Cancer Center) 相关的转化医学
100 项与 Neoantigen-Targeted Dendritic Cell Vaccine(Jonsson Comprehensive Cancer Center) 相关的专利(医药)
100 项与 Neoantigen-Targeted Dendritic Cell Vaccine(Jonsson Comprehensive Cancer Center) 相关的药物交易